Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.
Healthcare workers
Household transmission
SARS-CoV-2 antibodies
SARS-CoV-2 infection
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
06
04
2021
accepted:
06
09
2021
pubmed:
9
1
2022
medline:
15
2
2022
entrez:
8
1
2022
Statut:
ppublish
Résumé
This st udy aims to evaluate the prevalence of SARS-CoV-2 antibodies in locked-down family households to determine viral dynamics and immunity acquisition. COVID-19 individuals and their households in lockdown under the same roof during early spring 2020 were interviewed and tested using rapid immunochromatographic lateral flow antibodies assays (LFA) between July and September 2020. Outcomes were secondary infection rate (SIR) among contacts, household infection rate, and predictors of transmission. We enrolled 87 households including 87 COVID-19 index cases (female 78.2%; median age: 47.0 years, IQR: 42.0-51.5) and 255 contacts (males: 52.9%; median age: 19.0 years, IQR: 11.0-43.5) consisting of their children (42%) or spouses/partners (28.2%). A total of 95/255 contacts were SARS-CoV-2 antibody positive leading to a SIR of 37.3% (95% confidence interval (CI): 31.3-43.5%). Viral transmission was observed in 54 households (62%). SARS-CoV-2 infection was asymptomatic in 33/95 (34.7%) of SARS-CoV-2-positive contacts. Independent predictors of virus transmission from index to contacts were housing surface area < 60 m
Identifiants
pubmed: 34997388
doi: 10.1007/s10096-021-04345-9
pii: 10.1007/s10096-021-04345-9
pmc: PMC8741543
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-454Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
PLoS One. 2020 Sep 17;15(9):e0237694
pubmed: 32941461
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
J Hosp Infect. 2020 Dec;106(4):678-697
pubmed: 32956786
Nat Commun. 2021 Apr 16;12(1):2295
pubmed: 33863887
Clin Infect Dis. 2020 Nov 5;71(8):1953-1959
pubmed: 32382743
Ann Intern Med. 2020 Dec 1;173(11):879-887
pubmed: 32790510
Can J Public Health. 2021 Feb;112(1):12-16
pubmed: 33205377
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Clin Infect Dis. 2020 Dec 17;71(10):2719-2722
pubmed: 32701123
Rev Med Virol. 2021 Mar;31(2):e2162
pubmed: 32964627
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Ann Intern Med. 2021 Jan;174(1):69-79
pubmed: 32941052
JAMA Pediatr. 2020 Apr 8;:
pubmed: 32267485
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Clin Infect Dis. 2020 Nov 5;71(8):1943-1946
pubmed: 32301964
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Infect. 2020 Jul;81(1):179-182
pubmed: 32283139
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Nat Microbiol. 2021 Jan;6(1):11-18
pubmed: 33273742
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S138-S145
pubmed: 33045075
Clin Infect Dis. 2021 Jun 15;72(12):e970-e977
pubmed: 33180914
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Lancet Infect Dis. 2021 Mar;21(3):333-343
pubmed: 33152271
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
J Infect. 2020 Aug;81(2):e55-e58
pubmed: 32335168
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510